Sector News

GSK boosts board-level science

December 21, 2016
Life sciences

Drugmaker GlaxoSmithKline is bolstering scientific expertise on its board by establishing a new science committee, charged with overseeing research, as a new chief executive prepares to take over.

Incoming CEO Emma Walmsley, the first woman to lead a top global drugmaker, stands out among Big Pharma bosses as a consumer brands specialist rather than a prescription medicines expert.

Since her appointment in September she has spent much of her time learning about GSK’s prescription drug research and development (R&D), according to company insiders. She takes over from Andrew Witty at the end of March.

Britain’s biggest drugmaker said on Monday that its new science committee would be chaired by non-executive director Jesse Goodman, a former chief scientist for the U.S. Food and Drug Administration.

Patrick Vallance, president of R&D, will also join the GSK board as an executive director on Jan. 1, ahead of the retirement of current research head and board member Moncef Slaoui on March 31.

Despite GSK’s diversified structure, which includes vaccines and consumer health products, drug discovery remains a core activity and the company expects important clinical results for between 20 and 30 experimental medicines by the end of 2018.

Walmsley herself has described R&D as “the beating heart” of the group.

By Ben Hirschler

Source: Reuters

comments closed

Related News

May 15, 2022

Novo Nordisk and Flagship Pioneering announce a strategic collaboration to create a portfolio of transformational medicines

Life sciences

The companies will explore opportunities to apply Flagship’s innovative bioplatforms – an ecosystem that currently comprises 41 companies – to scientific challenges in disease areas within cardiometabolic and rare diseases and initiate research programmes based on these.

May 15, 2022

BD, Babson set sights on bringing simple blood collection into the home

Life sciences

BD is expanding its long-running partnership with the blood collection company Babson Diagnostics. The two companies have been working together since 2019 on a device that can gather small volumes of blood from the capillaries in the fingertip without requiring any specialized training, and beginning with a focus on supporting primary care in retail settings.

May 15, 2022

CSL’s $11.7B Vifor buy, 2021’s biggest biopharma M&A deal, hits antitrust delay

Life sciences

Wednesday, Australian biotech CSL said (PDF) the regulatory review of its $11.7 billion acquisition of Switzerland’s Vifor Pharma will take “a few more months,” suggesting it won’t be able to close the transaction by June 2022 as previously expected.